CareLit · DOI-Nachweis · Pneumologie
Interim analysis of nintedanib in an open-label extension of the INPULSIS® trials (INPULSIS®-ON)
DOI 10.1055/s-0036-1571997
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Kreuter, B Crestani, T Ogura, K Pelling, C Coeck, M Quaresma, M Kaye
ZeitschriftPneumologie
Ausgabe02/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: The INPULSIS® trials assessed the efficacy and safety of nintedanib 150 mg twice daily in patients with idiopathic pulmonary fibrosis. Nintedanib significantly reduced the annual rate of decline in forced vital capacity (FVC) compared with placebo in both trials. Patients who completed the 52-week treatment period and follow-up visit 4 weeks later (n = 807) could receive open-label nintedanib in an ext…
Zitieren
Zitierempfehlung
M Kreuter, B Crestani, T Ogura, K Pelling, C Coeck, M Quaresma, M Kaye (2016) Interim analysis of nintedanib in an open-label extension of the INPULSIS® trials (INPULSIS®-ON). Pneumologie (02). https://doi.org/10.1055/s-0036-1571997
Mit CareLit weiterarbeiten